Lili Cui

Lili Cui is currently the New Modality R&D Director at CSPC Pharmaceutical Group, where they lead research efforts in nucleic acid portfolios including mRNA, siRNA, ASO, and CRISPR. With extensive experience as a Senior Scientist at AstraZeneca, Lili initiated the mRNA LNP capability build and has effectively collaborated with multidisciplinary teams to deliver various drug development projects. They obtained a PhD in Pharmaceutical Science from King's College London, where their research focused on polymeric nanoparticles for targeted drug delivery. Lili’s prior roles include significant contributions at Silence Therapeutics, where they worked on novel lipid designs and formulation development for siRNA and mRNA delivery systems.